^
    2years
    Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=367, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    SYH2043